Dennis C Copertino Jr
Overview
Explore the profile of Dennis C Copertino Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howard J, Zaikos T, Levinger C, Rivera E, McMahon E, Holmberg C, et al.
JCI Insight
. 2024 Aug;
9(18).
PMID: 39115957
Nonreceptor tyrosine phosphatases (NTPs) play an important role in regulating protein phosphorylation and have been proposed as attractive therapeutic targets for cancer and metabolic diseases. We have previously identified that...
2.
HIV-1 subtype A1, D, and recombinant proviral genome landscapes during long-term suppressive therapy
Lee G, Khadka P, Gowanlock S, Copertino Jr D, Duncan M, Omondi F, et al.
Nat Commun
. 2024 Jul;
15(1):5480.
PMID: 38956017
The primary obstacle to curing HIV-1 is a reservoir of CD4+ cells that contain stably integrated provirus. Previous studies characterizing the proviral landscape, which have been predominantly conducted in males...
3.
Matveev V, Mihelic E, Benko E, Budylowski P, Grocott S, Lee T, et al.
iScience
. 2023 Oct;
26(10):107915.
PMID: 37790281
Older individuals and people with HIV (PWH) were prioritized for COVID-19 vaccination, yet comprehensive studies of the immunogenicity of these vaccines and their effects on HIV reservoirs are not available....
4.
Gunst J, Hojen J, Pahus M, Rosas-Umbert M, Stiksrud B, McMahon J, et al.
Nat Med
. 2023 Sep;
29(10):2547-2558.
PMID: 37696935
Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double-blinded trial, 43 people (85% males)...
5.
Copertino Jr D, Holmberg C, Weiler J, Ward A, Howard J, Levinger C, et al.
JCI Insight
. 2023 Aug;
8(18).
PMID: 37581929
IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination...
6.
Matveev V, Mihelic E, Benko E, Budylowski P, Grocott S, Lee T, et al.
bioRxiv
. 2023 Jul;
PMID: 37502977
Older individuals and people with HIV (PWH) were prioritized for COVID-19 vaccination, yet comprehensive studies of the immunogenicity of these vaccines and their effects on HIV reservoirs are not available....
7.
Duarte R, Copertino Jr D, Iniguez L, Marston J, Bram Y, Han Y, et al.
Mol Med
. 2021 Sep;
27(1):105.
PMID: 34503440
Background: Vaccination programs have been launched worldwide to halt the spread of COVID-19. However, the identification of existing, safe compounds with combined treatment and prophylactic properties would be beneficial to...
8.
Copertino Jr D, Casado Lima B, Duarte R, Powell T, Ormsby C, Wilkin T, et al.
J Biomol Struct Dyn
. 2021 Mar;
40(16):7367-7380.
PMID: 33734021
COVID-19 is the disease caused by SARS-CoV-2 which has led to 2,643,000 deaths worldwide, a number which is rapidly increasing. Urgent studies to identify new antiviral drugs, repurpose existing drugs,...
9.
Bortlik M, Copertino Jr D, Brailey P, Beckerle G, Ormsby C, Rosenberg M, et al.
Pediatr Infect Dis J
. 2021 Jan;
40(2):144-146.
PMID: 33395209
Introduction: Around 1.7 million children are estimated to live with HIV-1 worldwide, and about 160,000 infants are newly infected every year. Since adaptive immunity takes time to mature and develop...